Assessment of paraoxonase activities in patients with knee osteoarthritis

Redox Report

Volumn 13, Issue 5, 2008, Pages 194-198

  Soran, Neslihan ^a,c   Altindag, Ozlem ^b   Çakir, Hale ^a   Çelik, Hakim ^a   Demirkol, Ahmet ^a   Aksoy, Nurten ^a  

^a HARRAN UNIVERSITY   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c Ipekyol Mah Gazi Cad   (Turkey)

Author keywords

Arylesterase; Atherosclerosis; Knee osteoarthritis; Lipid hydroperoxide; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; FERROUS ION; HIGH DENSITY LIPOPROTEIN; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; THIOL; ANTIOXIDANT; CARBOXYLESTERASE; LIPID PEROXIDE; PON1 PROTEIN, HUMAN; THIOL DERIVATIVE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; LIPID PEROXIDATION; MALE; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; SPECTROPHOTOMETRY; BLOOD; ENZYMOLOGY;

ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CARBOXYLIC ESTER HYDROLASES; FEMALE; HUMANS; LIPID PEROXIDES; MALE; OSTEOARTHRITIS, KNEE; OXIDATIVE STRESS; SULFHYDRYL COMPOUNDS;

EID: 55549124890     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100008X308911     Document Type: Article

References (40)

1. Keuttner K, Godberg VM. (eds) Osteoarthritic Disorders. Rosemont, IL: American Academy of Orthopedic Surgeons, 1995; 21-25.
2. Mazzetti I, Grigolo B, Pulsatelli L et al. Differential roles of nitric oxide and oxygen radicals in chondrocytes affected by osteoarthritis and rheumatoid arthritis Clin Sci 2001; 101: 593-599.
3. Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003; 11: 747-755.
4. Sakurai H, Kohsaka H, Liu MF et al. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 1995, 96: 2357-2363.
5. Martel-Pelletier J, Alaeddine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999; 4: 694-703.
6. Yudoh K, Nguyen T, Nakamura H, Hongo-Masuko K, Kato T, Nishioka K. Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: oxidative stress induces chondrocyte telomere instability and downregulation of chondrocyte function. Arthritis Res Ther 2005; 7: 380-391.
7. Plaa GL, Witschi H. Chemicals, drugs and lipid peroxidation. Annu Rev Pharmacol Toxicol 1976; 16: 125.
8. Mapp PI, Grootveld MC, Blake DR. Hypoxia, oxidative stress and rheumatoid arthritis. Br Med Bull 1995; 51: 419-436.
9. Sato M, Miyazaki T, Nagaya T et al. Antioxidants inhibit tumor necrosis factor-alpha mediated stimulation of interleukin-8, monocyte chemoattractant protein-1 and collagenase expression in cultured human synovial cells. J Rheumatol 1996; 23: 432-438.
10. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-1046.
11. Stocker R, Keaney Jr JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478.
12. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
13. Epstein S, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 1999; 100: 20-28.
14. Niemela S, Karttunen T, Korhonen T et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 1996; 75: 573-575.
15. Hoffmeister A, Rothenbacher D, Bode G et al. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol 2001; 21: 427-432.
16. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
17. Canales A, Sanchez-Muniz FJ. Paraoxanase, something more than an enzyme? Med Clin (Barc) 2003; 121: 537-548.
18. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993; 211: 871-879.
19. Aslan M, Kosecik M, Horoz M, Selek S, Celik H, Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 2007; 191: 397-402.
20. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005; 16: 393-399.
21. Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-1138.
22. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C. 3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992; 30: 391-395.
23. Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 1999; 300: 58-62.
24. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77.
25. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 1993; 121: 257-262.
26. Mankin HJ, Mow VC, Buckwalter JA. Articular cartilage repair and osteoarthritis. In: Buckwalter JA, Einhorn TA, Simon SR. (eds) Orthopedic Basic Science, 2nd edn. Rosemont, IL: American Academy of Orthopedic Surgeons, 2000; 471-488.
27. Melchiorri C, Meliconi R, Frizziero L et al. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 1998; 41: 2165-2174.
28. Grabowski PS, Wright PK, Van't Hof RJ, Helfrich MH, Ohshima H, Ralston SH. Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1997; 36: 651-655.
29. Loeser RF, Carlson CS, Del Carlo M, Cole A. Detection of nitrotyrosine in aging and osteoarthritic cartilage: correlation of oxidative damage with the presence of interleukin-1beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum 2002; 46: 2349-2357.
30. Haidara MA, Yassin HZ, Rateb M, Ammar H, Zorkani MA. Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr Vasc Pharmacol 2006; 4: 215-227.
31. Arlt S, Kontush A, Muller-Thomsen T, Beisiegel U. [Lipid peroxidation as a common pathomechanism in coronary heart disease and Alzheimer disease]. Z Gerontol Geriatr 2001; 34: 461-465.
32. Esterbauer H, Wag G, Puhl H. Lipid peroxidation and its role in atherosclerosis. Br Med Bull 1993; 49: 566-576.
33. Mackness MI, Harty D, Bhatnagar D et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-199.
34. Paragh G, Seres I, Balogh Z et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998; 80: 166-170.
35. McElven J, Mackness MI, Colley CM et al. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986; 32: 671-673.
36. Deakin S, Moren X, James RW. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 2005; 179: 17-25.
37. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis 2006; 187: 74-81.
38. Mackness B, Durington P, McElduff P et al. Low paraoxonase activity predicts coronary events in the caterphilly prospective study. Circulation 2003; 107: 2775-2779.
39. Rozenberg O, Aviram M. S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem Biophys Res Commun 2006; 351: 492-498.
40. Gur M, Aslan M, Yildiz A et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006; 36: 779-787.